A trial tested a new antidepressant. Average symptom-score reductions (out of 50): placebo, -3.2; low dose, -8.4; medium dose, -14.1; high dose, -14.5. The researchers argued that the drug provides clear benefit, but doses above the medium level provide no further benefit. The strongest support for "no further benefit at high dose" is ______
Which choice most logically completes the text using the data above?
- Acheck_circle
the near-identical drops at medium (-14.1) and high doses (-14.5).
- B
the placebo's -3.2 reduction.
- C
the low dose's -8.4 reduction.
- D
the gap between placebo and high dose.
Explanation
"No further benefit at high dose" requires showing the medium-to-high jump produces almost no change. Choice B captures this 0.4-point flat comparison.